These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28124511)

  • 121. Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection.
    Huffman V; Andrade DC; Sherman E; Niu J; Eckardt PA
    Am J Health Syst Pharm; 2021 Jan; 78(1):36-40. PubMed ID: 33037429
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube.
    Jindracek L; Stark J
    J Pharm Pract; 2018 Oct; 31(5):522-524. PubMed ID: 28925327
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
    Bruno G; Saracino A; Fabrizio C; Scudeller L; Milano E; Dell'Acqua R; Ladisa N; Fasano M; Minniti S; Buccoliero G; Tartaglia A; Giammario A; Milella M; Angarano G
    Int J Antimicrob Agents; 2017 Mar; 49(3):296-301. PubMed ID: 28163136
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.
    Gamal N; Andreone P
    Expert Opin Drug Saf; 2016; 15(4):549-57. PubMed ID: 26899025
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
    Gane EJ; Hyland RH; An D; Svarovskaia ES; Brainard D; McHutchison JG
    Antivir Ther; 2016; 21(7):605-609. PubMed ID: 27367295
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
    Marciano S; Haddad L; Reggiardo MV; Peralta M; Vistarini C; Marino M; Descalzi VI; D'Amico C; Figueroa Escuti S; Gaite LA; Perez Ravier R; Longo C; Borzi SM; Galdame OA; Bessone F; Fainboim HA; Frías S; Cartier M; Gadano AC
    J Med Virol; 2018 May; 90(5):951-958. PubMed ID: 29350402
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    Øvrehus ALH; Krarup H; Birkemose I; Holm DK; Mössner B; Ernst A; Christensen PB
    J Hepatol; 2018 Apr; 68(4):840-842. PubMed ID: 29223370
    [No Abstract]   [Full Text] [Related]  

  • 131. Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
    Boglione L; De Nicolò A; Di Perri G; D'Avolio A
    Antivir Ther; 2019; 24(7):553-555. PubMed ID: 31502554
    [No Abstract]   [Full Text] [Related]  

  • 132. Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
    Pop CS; Preda CM; Manuc M; Gheorghe LS; Istratescu D; Chifulescu AE; Voiosu T; Diculescu M; Tieranu C; Iliescu L
    J Gastrointestin Liver Dis; 2020 Dec; 29(4):690-691. PubMed ID: 33331348
    [No Abstract]   [Full Text] [Related]  

  • 133. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
    Spooner LM; Abraham GM
    Am J Health Syst Pharm; 2017 Apr; 74(8):555. PubMed ID: 28389452
    [No Abstract]   [Full Text] [Related]  

  • 134. Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
    Obed A; Bashir A; Jarrad A
    Am J Case Rep; 2016 Sep; 17():672-5. PubMed ID: 27647003
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
    Ou P; Fang Z; Chen J
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e17-e18. PubMed ID: 27601170
    [No Abstract]   [Full Text] [Related]  

  • 136. Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
    D'Ambrosio R; Aghemo A; Rossetti V; Carrinola R; Colombo M
    Liver Int; 2016 Nov; 36(11):1585-1589. PubMed ID: 27429162
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
    Stern R; Hametner S; Ramona AZ; Moser S; Karpi A; Laferl H; Stauber RE; Zoller HM; Maieron A; Vogel W; Graziadei I; Gschwantler M; Kozbial K; Freissmuth C; Hofer H; Ferenci P
    Am J Gastroenterol; 2016 May; 111(5):744-5. PubMed ID: 27151123
    [No Abstract]   [Full Text] [Related]  

  • 138. Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
    Taramasso L; Ricci E; Celesia BM; Bonfanti P; Quirino T; Squillace N; Nicolini LA; Maggi P; Martinelli C; De Socio GV; Di Biagio A;
    Clin Res Hepatol Gastroenterol; 2017 Oct; 41(5):e76-e79. PubMed ID: 28438572
    [No Abstract]   [Full Text] [Related]  

  • 139. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient.
    Taibi C; Tempestilli M; D'Avolio A; Garbuglia AR; De Nicolò A; Montalbano M; D'Offizi G
    J Clin Pharm Ther; 2017 Oct; 42(5):621-623. PubMed ID: 28474408
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
    Gentile I; Borgia G
    Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.